With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
RICHMOND, Va. -- Another glimpse of hope for the more than 100,000 Americans with sickle cell anemia. The FDA recently approved two breakthrough gene therapies that can now be used to treat and ...
Groundbreaking advancements in gene therapy at UTMB represent new possibilities for patients living with rare genetic ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
A MeiraGTx Holdings gene therapy for Parkinson’s disease has preliminary data from a small clinical trial showing the one-time treatment showed both safety and efficacy, results that lay the ...
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...
Gazi University in Ankara has officially launched the production process for Türkiye's first local and national gene therapy research product. The project, which targets rare genetic diseases, is ...
The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission ...
News Medical on MSN
Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only If Costly Gene Therapies Work
Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends. It was a contrast to how Cole, 18, spent part of the 2024 holiday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results